Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.

Cancer Med · 2016 · PMC4944867 · PMID 27109549

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

marginally significantP = 0.055so close (0.05 < p ≤ 0.1)

However, sVEGFR2 levels significantly decreased in all nine patients by C1D14 after exposure to sunitinib ( P = 0.004), and showed a marginally significant decrease from days 1 to day 28 ( P = 0.055).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.